Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

for
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Location: Boston MA, New York NY, Tampa FL, Chicago IL,
Sponsor: Elevar Therapeutics

Sex: All

Age: 18+

Code: NCT07359820

Phase 2, Recruiting
Active & Responsive

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07075185

Phase 1, Recruiting
Active & Responsive

A Study of TAK-505 in Adults With Solid Tumors

for
Malignant Solid Tumors
Location: New York NY, Fairfax VA, Tampa FL, Cleveland OH,
Sponsor: Takeda

Sex: All

Age: 18+

Code: NCT07436728

Phase 1, Phase 2, Recruiting
Active & Responsive

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

for
Breast Cancer, Residual Disease,
Location: Chapel Hill NC, Birmingham AL
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT07069595

Phase 2, Recruiting
Active & Responsive

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

for
AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma,
Location: New York NY, Orange CA
Sponsor: Rigel Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07486713

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07477886

Recruiting
Active & Responsive

Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients

for
Advanced Cancer
Location: Palo Alto CA
Sponsor: Cancer Commons

Sex: All

Age: 0+

Code: NCT07343024

Recruiting
Active & Responsive

Life at 100.4: An Immersive Social Virtual Reality (VR) Education Tool for Adolescent and Young Adult Cancer Patients and Caregivers

for
Cancer, Adolescent Cancer, Young Adult Cancer
Location: New Haven CT
Sponsor: Yale University

Sex: All

Age: 13 - 39

Code: NCT07224204

Recruiting
Active & Responsive

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

for
Advanced Solid Tumors, Metastatic Solid Tumors,
Location: Norwich CT, New York NY, Hackensack NJ, Fairfax VA,
Sponsor: Revolution Medicines, Inc.

Sex: All

Age: 18+

Code: NCT07397338

Phase 1, Phase 2, Recruiting
Active & Responsive

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

for
Solid Tumors (Phase 1), RAS Mutation
Location: Orlando FL, Houston TX
Sponsor: Adlai Nortye Biopharma Co., Ltd.

Sex: All

Age: 18+

Code: NCT07252479

Phase 1, Recruiting
Active & Responsive

iCANSleep: Smartphone App-Based Insomnia Treatment for Cancer Survivors

for
Insomnia, Cancer
Location: St. John's
Sponsor: Memorial University of Newfoundland

Sex: All

Age: 18+

Code: NCT07101302

Recruiting
Active & Responsive

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

for
Solid Tumor
Location: New Haven CT, Charleston SC, Denver CO, Portland OR
Sponsor: Axcynsis Therapeutics Pte Ltd

Sex: All

Age: 18+

Code: NCT06809114

Phase 1, Recruiting
Active & Responsive

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

for
Malignant Neoplasm
Location: Quebec, New Brunswick NJ, Montreal, Fairfax VA, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07247110

Phase 1, Recruiting
Active & Responsive

Study of PAT in Patients With Solid Tumor Cancers

for
Metastasis, Solid Tumor
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT05338658

Phase 1, Recruiting
Active & Responsive

The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes

for
Insulin Dependent Diabetes Mellitus,
Location: Montreal
Sponsor: McGill University

Sex: All

Age: 12+

Code: NCT07348432

Recruiting
Active & Responsive

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT06414278

Recruiting
Active & Responsive

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

for
Advanced Solid Cancers
Location: New York NY, Orlando FL, Detroit MI, Denver CO
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07186842

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: New Haven CT, Philadelphia PA, Fairfax VA,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT07213817

Phase 1, Phase 2, Recruiting
Active & Responsive

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

for
Malignant Neoplasm
Location: Clermont FL, Fargo ND, Sioux Falls SD
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07252739

Phase 2, Recruiting
Active & Responsive

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

for
Advanced Solid Tumor, Metastatic Solid Tumor
Location: Toronto, Grand Rapids MI, Nashville TN, Houston TX,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT07213830

Phase 1, Phase 2, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial